- Investing Ideas
- Global Pharmaceuticals & Biotech Top Growth Stocks
Global Pharmaceuticals & Biotech Top Growth Stocks
Results
66
66 companies
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$97.0b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$415.80
7D
0.1%
1Y
29.1%
Madrigal Pharmaceuticals
Market Cap: US$11.7b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$505.75
7D
5.2%
1Y
77.0%
Beijing Luzhu Biotechnology
Market Cap: HK$2.5b
A biotechnology company, develops human vaccines and therapeutic biologics to prevent and control infectious diseases, and to treat cancer and autoimmune diseases in Mainland China.
2480
HK$12.75
7D
3.2%
1Y
-48.8%
Oscotec
Market Cap: ₩1.4t
Operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses.
A039200
₩37,150.00
7D
-5.0%
1Y
31.3%
Camurus
Market Cap: SEK 30.9b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMX
SEK 519.00
7D
-3.7%
1Y
-10.8%
Syndax Pharmaceuticals
Market Cap: US$1.7b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$19.00
7D
4.1%
1Y
100.4%
HansBiomed
Market Cap: ₩349.4b
Engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies.
A042520
₩24,500.00
7D
-3.5%
1Y
171.6%
Kuros Biosciences
Market Cap: CHF 739.9m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURN
CHF 18.50
7D
-9.8%
1Y
-27.5%
Guangzhou Innogen Pharmaceutical Group
Market Cap: HK$3.4b
Engages in the development of drug engaged in the research, development and commercialization of pharmaceutical products.
2591
HK$7.54
7D
-10.0%
1Y
n/a
Bonesupport Holding
Market Cap: SEK 13.9b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEX
SEK 210.60
7D
-7.4%
1Y
-21.7%
Ardelyx
Market Cap: US$1.5b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$6.05
7D
6.3%
1Y
69.9%
Cutia Therapeutics
Market Cap: HK$1.2b
An investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong.
2487
HK$3.20
7D
-0.6%
1Y
-66.2%
Pharma Mar
Market Cap: €1.2b
A biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally.
PHM
€69.50
7D
3.7%
1Y
-14.9%
Ocumension Therapeutics
Market Cap: HK$4.0b
Engages in the research, discovery, development, and commercialization of ophthalmic therapies in China.
1477
HK$4.89
7D
-6.9%
1Y
-53.4%
Alnylam Pharmaceuticals
Market Cap: US$37.1b
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
ALNY
US$278.09
7D
-1.7%
1Y
-10.2%
Forum Markets
Market Cap: US$73.4m
A financial technology company, develops a blockchain-based platform focused on the acquisition, structuring, and tokenization of real-world assets worldwide.
FRMM
US$5.05
7D
-5.6%
1Y
-41.6%
Capricor Therapeutics
Market Cap: US$1.6b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$28.38
7D
10.0%
1Y
243.6%
ARS Pharmaceuticals
Market Cap: US$958.3m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
SPRY
US$9.65
7D
-1.1%
1Y
-38.9%
MindMaze Therapeutics Holding
Market Cap: CHF 35.3m
Operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally.
MMTX
CHF 0.22
7D
-22.9%
1Y
n/a
Bora Pharmaceuticals
Market Cap: NT$53.8b
Engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally.
6472
NT$422.50
7D
8.2%
1Y
-37.0%
CG Oncology
Market Cap: US$5.4b
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CGON
US$61.08
7D
2.6%
1Y
139.1%
Oxford Biomedica
Market Cap: UK£734.0m
A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
OXB
UK£6.00
7D
0%
1Y
86.9%
BioStem Technologies
Market Cap: US$70.9m
Engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.
BSEM
US$4.00
7D
-2.0%
1Y
-70.9%
Arcutis Biotherapeutics
Market Cap: US$3.3b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$26.21
7D
7.5%
1Y
89.7%
Belite Bio
Market Cap: US$5.7b
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States.
BLTE
US$146.12
7D
5.8%
1Y
141.6%
NewAmsterdam Pharma
Market Cap: US$3.5b
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
NAMS
US$29.83
7D
-1.9%
1Y
66.1%
Insmed
Market Cap: US$20.8b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$95.80
7D
-2.1%
1Y
-6.7%
SIGA Technologies
Market Cap: US$309.8m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$4.32
7D
0%
1Y
-29.4%
Genovis AB (publ.)
Market Cap: SEK 1.2b
Develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia.
GENO
SEK 18.32
7D
-6.4%
1Y
-33.1%
Devyser Diagnostics
Market Cap: SEK 1.5b
Provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa.
DVYSR
SEK 86.70
7D
-3.3%
1Y
-21.9%
Healios K.K
Market Cap: JP¥34.8b
Engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States.
4593
JP¥258.00
7D
-1.1%
1Y
-42.8%
Cosmo
Market Cap: CHF 1.1b
A life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally.
COPN
CHF 68.50
7D
-2.0%
1Y
22.8%
argenx
Market Cap: €47.4b
A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
ARGX
€773.80
7D
-1.3%
1Y
64.3%
Cantourage Group
Market Cap: €77.8m
Operates as a medical cannabis company in Europe and internationally.
HIGH
€6.16
7D
-1.0%
1Y
6.2%
Everest Medicines
Market Cap: HK$9.4b
A biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets.
1952
HK$26.68
7D
-3.7%
1Y
-45.6%
Medexus Pharmaceuticals
Market Cap: CA$130.8m
Operates as a pharmaceutical company in Canada and the United States.
MDP
CA$4.20
7D
4.7%
1Y
30.4%